Promoting Independence With Compensatory Cognitive Rehabilitation
NCT04820335
Summary
Alzheimer's disease (AD) is one of the leading causes of disability in older adults. Because pharmacological approaches do not seem to prevent or slow the disease, clinicians need non-pharmacological interventions that might help people with AD remain independent for as long as possible. This study aims to evaluate the effects of a new behavioral treatment, the Structured External Memory Aid Treatment (SEMAT), for adults with mild cognitive impairment (MCI) designed to promote independent living skills by explicitly teaching the use of strategies and tools to compensate for cognitive weaknesses. Aim 1: Evaluate the efficacy of the SEMAT for improving functional performance in a pilot randomized trial. Aim 2: Evaluate demographic, clinical, and neuropsychological predictors of treatment adherence. Aim 3: Develop and refine the SEMAT manual and other materials for training future interventionists.
Eligibility
Inclusion Criteria * 60-90 years of age * English Speaking * Functional Vision and Hearing to Complete Phone Screen * not taking or stable ( \>2 months) on nootropic meds * amnestic mild cognitive impairment from probable Alzheimer's disease Exclusion Criteria * History of major psychiatric disorder (e.g. schizophrenia) * Untreated major depression * History of medical diseases that are related to cognitive impairment * current participation in another clinical trial related to memory * major auditory, visual, or motor impairment that would affect their ability to participate in the study * substance use disorder in the past 5 years
Conditions3
Locations1 site
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT04820335